Bausch Health Companies Inc. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- Bausch Health Companies Inc. payments for repurchase of common stock for the quarter ending 2016-12-31 was $0.00, a 100.00% decline year-over-year.
- Bausch Health Companies Inc. payments for repurchase of common stock for the quarter ending 2016-09-30 was $0.00.
- Bausch Health Companies Inc. payments for repurchase of common stock for the quarter ending 2015-12-31 was $22.00M.
- Bausch Health Companies Inc. payments for repurchase of common stock for the quarter ending 2015-09-30 was $0.00.
- Bausch Health Companies Inc. payments for repurchase of common stock for fiscal 2014 was $0.00, a 100.00% decline from fiscal 2013.
- Bausch Health Companies Inc. payments for repurchase of common stock for fiscal 2013 was $55.60M, a 80.19% decline from fiscal 2012.
- Bausch Health Companies Inc. payments for repurchase of common stock for fiscal 2012 was $280.70M, a 56.09% decline from fiscal 2011.
- Bausch Health Companies Inc. payments for repurchase of common stock for fiscal 2011 was $639.24M, a 963.10% increase from fiscal 2010.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2017-12-31 | $0.00 8-K · filed 2018-08-10 | |
| 2016-12-31 | $0.00 derived: 8-K 12 month − 10-Q 9 month · filed 2018-08-10 | $0.00 8-K · filed 2018-08-10 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | |
| 2015-12-31 | $22.00M derived: 8-K 12 month − 10-Q 9 month · filed 2018-08-10 | $72.00M 8-K · filed 2018-08-10 |
| 2015-09-30 | $0.00 10-Q · filed 2015-10-26 | |
| 2015-06-30 | $50.00M 10-Q · filed 2015-07-28 | |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $0.00 10-K · filed 2017-03-01 |
| 2014-09-30 | $0.00 10-Q · filed 2015-10-26 | $0.00 derived: sum of 4 quarters · filed 2016-04-29 |
| 2014-06-30 | $0.00 10-Q · filed 2015-07-28 | $0.00 derived: sum of 4 quarters · filed 2016-04-29 |
| 2014-03-31 | $0.00 10-Q · filed 2014-05-09 | $20.60M derived: sum of 4 quarters · filed 2016-04-29 |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-04-29 | $55.60M 10-K · filed 2016-04-29 |
| 2013-09-30 | $0.00 10-Q · filed 2014-10-24 | $55.58M derived: sum of 4 quarters · filed 2015-02-25 |
| 2013-06-30 | $20.60M 10-Q · filed 2014-08-01 | $55.58M derived: sum of 4 quarters · filed 2015-02-25 |
| 2013-03-31 | $35.00M 10-Q · filed 2014-05-09 | $206.98M derived: sum of 4 quarters · filed 2015-02-25 |
| 2012-12-31 | -$24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-25 | $280.70M 10-K · filed 2015-02-25 |
| 2012-09-30 | $0.00 10-Q · filed 2013-11-01 | $345.85M derived: sum of 4 quarters · filed 2014-02-28 |
| 2012-06-30 | $172.00M 10-Q · filed 2013-08-07 | $420.40M derived: sum of 4 quarters · filed 2014-02-28 |
| 2012-03-31 | $108.72M 10-Q · filed 2013-05-03 | $473.22M derived: sum of 4 quarters · filed 2014-02-28 |
| 2011-12-31 | $65.12M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $639.24M 10-K · filed 2014-02-28 |
| 2011-09-30 | $74.56M 10-Q · filed 2012-11-05 | |
| 2011-06-30 | $224.81M 10-Q · filed 2012-08-03 | |
| 2011-03-31 | $274.75M 10-Q · filed 2012-05-04 | |
| 2010-12-31 | $60.13M 10-K · filed 2013-02-28 | |
| 2008-12-31 | $29.84M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |